Published in Nat Rev Clin Oncol on July 01, 2009
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 2.65
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol (2008) 1.13
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol (2009) 1.57
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma (2002) 1.46
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.43
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.33
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood (2008) 1.27
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood (2002) 1.19
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One (2011) 1.12
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol (2008) 1.09
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol (2002) 1.09
Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol (2008) 1.07
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
Expression of mesenchyme-specific gene signatures by follicular dendritic cells: insights from the meta-analysis of microarray data from multiple mouse cell populations. Immunology (2011) 1.04
The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res (2014) 1.04
Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res (2011) 1.02
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett (2012) 1.01
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol (2012) 1.00
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol (2014) 0.98
Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer (2010) 0.95
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res (2011) 0.93
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2002) 0.93
CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol (2002) 0.89
Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet (2010) 0.89
Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol (2003) 0.89
Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol (2010) 0.88
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.88
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol (2014) 0.88
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. Br J Haematol (2014) 0.86
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res (2012) 0.86
Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol (2004) 0.85
Epstein-barr virus-associated diffuse large B-cell lymphoma in an immunocompetent woman. J Clin Oncol (2009) 0.85
Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma. J Clin Oncol (2004) 0.85
Novel presentation of intraneural nodular fasciitis of the sciatic nerve. J Peripher Nerv Syst (2007) 0.84
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet (2010) 0.83
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res (2004) 0.83
Biopolymer and water dynamics in microbial biofilm extracellular polymeric substance. Biomacromolecules (2008) 0.83
The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma (2002) 0.83
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys (2011) 0.83
Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol (2012) 0.81
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol (2013) 0.81
Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma (2013) 0.81
Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol (2010) 0.81
Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk (2010) 0.81
Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol (2010) 0.80
Primary bone lymphoma involving bilateral tibia. Am J Hematol (2012) 0.80
Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol (2010) 0.79
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.79
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma (2013) 0.78
AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter. J Clin Oncol (2007) 0.78
Magnetic resonance microscopy determined velocity and hematocrit distributions in a Couette viscometer. Biorheology (2005) 0.78
Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells. Leuk Lymphoma (2015) 0.78
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Options Oncol (2006) 0.78
Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Semin Hematol (2008) 0.77
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma (2014) 0.76
One size does not fit all in follicular lymphoma. J Clin Oncol (2013) 0.76
Genomic approaches to chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2013) 0.76
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica (2013) 0.76
Microbial and algal alginate gelation characterized by magnetic resonance. J Biotechnol (2012) 0.76
Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs (2015) 0.76
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res (2013) 0.75
First-line treatment of indolent lymphoma: axing CHOP? Lancet (2013) 0.75
Early initial therapy of advanced follicular lymphoma: the need for vigilance. Leuk Lymphoma (2011) 0.75
Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2013) 0.75
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma (2014) 0.75
Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet? Oncology (Williston Park) (2016) 0.75
Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]. Hematology Am Soc Hematol Educ Program (2011) 0.75